Pierre Kerbrat

TL;DR: The 10-year and 15-year effects of various systemic adjuvant therapies on breast cancer recurrence and survival are reported and it is found that the cumulative reduction in mortality is more than twice as big at 15 years as at 5 years after diagnosis.

TL;DR: Weekly paclitaxel at the dose schedule used in the current study was well tolerated and demonstrated clinical benefit, and anemia and fatigue were the most frequently reported toxicities.

TL;DR: The PACS 01 trial as mentioned in this paper compared six cycles of fluorouracil, epirubicin, and cyclophosphamide (FEC) with a sequential regimen of three cycles of FEC followed by three cycle of docetaxel as adjuvant treatment for node-positive early breast cancer.

TL;DR: Sequential adjuvant chemotherapy with FEC followed by docetaxel significantly improves disease-free and overall survival in node-positive breast cancer patients and has a favorable safety profile.

TL;DR: Imatinib interruption results in rapid progression in most patients with advanced GIST, and cannot be recommended in routine practice unless patient experience significant toxicity.